

Haematologica
HAEMATOL/2019/233189
Version 4

Severe treatment-refractory T-cell-mediated immune skin toxicities
observed with obinutuzumab/rituximab-atezo-pola in two patients with
follicular lymphoma

Max S. Topp, Johannes Duell, Ana Maria Abajo Guijarro, Marielle Odin,
Tina Nielsen, Anand Rajeswaran, Michael Wenger, Christelle Zundel,
Aleksandra Bogucka-Fedorczuk, and Tomasz Wrobel

Disclosures: M.W., T.N., A.M.A.G., M.O., A.R., and C.Z. reported employment at Roche/Genentech. T.N., A.R., A.M.A.G., M.O., and M.W. declared stock ownership at Roche/Genentech. M.S.T. reported research grants from Amgen Inc, Gilead, MacroGenics, Roche, CONFIDENTIAL: FOR PARTICIPANT REVIEW ONLY 6 and Regeneron; consulting fees from Amgen and Roche; and advisory board membership for Amgen and Regeneron. T.W. reported research grants, advisory board membership from Roche, Amgen, and Novartis; lecture fees from Roche, Novartis, and Celgene; and advisory board membership for Celgene. The remaining authors declare no competing interests.

Contributions: A.M.A.G., T.W. and M.W. conceived and designed the study; M.S.T., J.D., T.W., A.B.F. and C.Z. provided study materials or patients; M.S.T., J.D., T.W., A.B.F., M.W., M.O. and A.M.A.G. collected and assembled the data; M.S.T., J.D., A.M.A.G., A.R., T.W., M.W., M.O. and T.N. analyzed and interpreted the data; all authors wrote and had final approval of the manuscript and are accountable for all aspects of the work.